Accordingly, V1bR antagonists did not show statistically significant efficacy in clinical trials for major depressive disorder and generalized anxiety disorder (Griebel et al, 2012; Chaki, 2021; Kamiya et al, 2020). The gene discussed is AVPR1B; the disease is major depressive disorder.